Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "Heterogeneous nuclear ribonucleoprotein A1-like 2 pseudogene" (ENSG00000269014) is a **pseudogene**, which means it is a DNA sequence resembling a functional gene but is generally incapable of producing a functional protein product[1][3]. Pseudogenes often arise through gene duplication or retrotransposition; they retain sequence homology to their functional counterparts but accumulate disabling mutations, such as frameshifts or premature stop codons, rendering them nonfunctional[1][3][5]. Specifically, this pseudogene is derived from a member of the heterogeneous nuclear ribonucleoproteins (hnRNPs), which are RNA-binding proteins involved in pre-mRNA processing, but the "A1-like 2 pseudogene" is not believed to encode an active protein. While many pseudogenes are "junk DNA," recent research shows some pseudogenes may have regulatory roles as long noncoding RNAs, antisense RNAs, or microRNA decoys, influencing gene expression of their parent genes or other targets[2][3][5]. However, there is no publicly available evidence that this specific pseudogene (ENSG00000269014) is functionally relevant or actively transcribed. Because pseudogenes are not considered direct therapeutic targets (they do not encode proteins or have established pathogenic functions as targets), and database convention treats entries like ENSG00000269014 as nonfunctional, **it is not a therapeutic target and is generally not considered a correct answer for molecular target queries regarding drug discovery or pharmacology**[1][3]. If you are seeking a druggable gene or protein, this entry is likely misspecified or not actionable for pharmaceutical purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein A1-like 2 pseudogene.